Abstract | The mTOR pathway has a central role in the regulation of cell metabolism, growth and proliferation. Studies involving selective gene targeting of mTOR complexes (mTORC1 and mTORC2) in renal cell populations and/or pharmacologic mTOR inhibition have revealed important roles of mTOR in podocyte homeostasis and tubular transport. Important advances have also been made in understanding the role of mTOR in renal injury, polycystic kidney disease and glomerular diseases, including diabetic nephropathy. Novel insights into the roles of mTORC1 and mTORC2 in the regulation of immune cell homeostasis and function are helping to improve understanding of the complex effects of mTOR targeting on immune responses, including those that impact both de novo renal disease and renal allograft outcomes. Extensive experience in clinical renal transplantation has resulted in successful conversion of patients from calcineurin inhibitors to mTOR inhibitors at various times post-transplantation, with excellent long-term graft function. Widespread use of this practice has, however, been limited owing to mTOR-inhibitorrelated toxicities. Unique attributes of mTOR inhibitors include reduced rates of squamous cell carcinoma and cytomegalovirus infection compared to other regimens. As understanding of the mechanisms by which mTORC1 and mTORC2 drive the pathogenesis of renal disease progresses, clinical studies of mTOR pathway targeting will enable testing of evolving hypotheses. NATURE REVIEWS | NEPHROLOGY VOLUME 12 | OCTOBER 2016 | 587
Since the discovery of rapamycin (also known as siroli mus) more than 40 years ago 1 , advances in the under standing of its molecular mode of action as well as the functional biology of its primary target -mTOR -have permeated many areas of medicine, including cardio vascular disease, autoimmunity and cancer. mTOR is an evolutionarily conserved serine-threonine kinase that regulates cell growth, proliferation and metabo lism. Increasing evidence indicates that mTOR has an important role in the regulation of renal cell homeostasis and autophagy. Moreover, this kinase has been impli cated in the development of glomerular disease, poly cystic kidney disease (PKD), acute kidney injury (AKI) and kidney transplant rejection.
The development of rapamycin and its analogues (known as rapalogues) temsirolimus and everolimus, has expanded the pharmacological armamentarium for treatment of renal disease. Owing to its ability to potently inhibit Tcell proliferation, rapamycin was initially devel oped as an immunosuppressive agent in kidney trans plantation 2 . Rapalogues have now also been added to the immunosuppressive repertoire for glomerulonephritides (although they are not currently a therapeutic mainstay for these conditions) and renal cell carcinoma (RCC). In this Review, we discuss aspects of mTOR function and its inhibition in relation to renal physiology, kidney disease including malignancy, and the role of mTOR complexes and their inhibitors in renal transplantation. mTOR complexes mTOR operates in at least two distinct, multiprotein complexes: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2) (FIG. 1) . Details of the structural biochemistry of mTOR and its role in cellular signalling have been reviewed in detail elsewhere [3] [4] [5] . mTORC1 is often described as a 'nutrient sensor' as it can be acti vated by amino acids and inhibited by severe oxidative stress and energy depletion. The primary roles of mTOR are to facilitate cell growth and anabolism as well as to prevent autophagy. Although mTORC1 was localized initially to the cytoplasm, this complex has since been identified in association with endosomal compartments (outer mitochondrial membranes and nuclei [6] [7] [8] ) and has been shown to have a role in stress granule formation 9 . These findings provide further evidence that mTOR is a 'metabolic rheostat' for eukaryotic cells.
Growth factors and cytokines can activate mTORC1 via upstream signalling through phosphoinositide 3kinase (PI3K). Generation of phosphatidylino sitol (3, 4, 5) triphosphate (PIP3) by PI3K activates 3phosphoinositidedependent protein kinase1 (PDK1), which enhances Akt (also known as protein kinase B) activity by phosphorylating the activation loop at threo nine 308. Interestingly, mTORC2 uniquely stabilizes Akt via phosphorylation of the turn motif at serine 450, and further stimulates Akt kinase activity by phosphory lating the hydrophobic motif at serine 473. The activity of tuberous sclerosis complex 1 (TSC1) and TSC2, the major upstream inhibitors of mTORC1, is dampened directly by Aktdependent phosphorylation and pro vides a functional link between the PI3K-Akt signalling axis and mTOR. TSC1 stabilizes and TSC2 inhibits the activity of the guanosine triphosphate (GTP)ase Rheb (RAS homologue enriched in brain), through its GTPase activating protein activity. Rheb enhances the catalytic activity of mTORC1 when they are in close proximity.
Tools to study mTORC2 are limited owing to a lack of mTORC2specific inhibitors. Substrates of mTORC2 include Akt, protein kinase Cα (PKCα) and serum and glucocorticoidinduced kinase1 (SGK1). Furthermore, phosphorylation and cytoplasmic sequestration of the forkhead box proteins 01 (FOXO1) and FOXO3 by Akt has been shown to require mTORC2 (REF. 10 ). Consistent with these signalling cascades, mTORC2orchestrated processes include cell survival, protein synthesis, reor ganization of the actin cytoskeleton and sodium homeo stasis. Although active mTORC2 physically associates with ribosomes in mammalian cells, the intricacies of this pathway have not been completely characterized 11 . Importantly, crosstalk between the mTORC1 and mTORC2 pathways 12 adds an extra layer of complexity in dissecting mTORC1 and mTORC2 biology. Thus, mTORC1 inhibits the PI3K-mTORC2 pathway through a negative feedback mechanism. mTOR inhibitors Although rapamycin immediately inhibits mTORC1, its ability to destabilize and inhibit mTORC2 requires prolonged exposure and is more sensitive to fluctuations in concentrations of the immunophilin FK506 binding protein 12 (FKBP12), which binds rapamycin and medi ates its interaction with mTOR 13 . The negligible effect of rapamycin on mTORC2 function has been disputed, however, with evidence that this agent might inhibit mTORC2 assembly and signalling 14 . The Cterminal part of Avo3, a subunit unique to TORC2 in yeast, is located close to the FKBP12/rapamycinbinding domain of mTORC2, and removal of Avo3 from TORC2 con fers sensitivity to rapamycin 15 . Little is known about the effects of rapalogues on mTORC1 and mTORC2, but everolimus and temsirolimus have been shown to inhibit mTORC2 activity in myeloid leukaemia cells 16 . Novel dual inhibitors of TORC1 and TORC2 (TORKinibs) that compete for the adenosine triphos phate (ATP)binding site of mTOR were developed to limit activation of both mTOR complexes 17 and pro vide broader clinical efficacy than the currently avail able rapalogues. These molecules were first described to inhibit P13K 17 , a critical component upstream of the Akt/mTOR pathway, and subsequently also found to inhibit mTOR, presumably owing to sequence homol ogy. Initial TORKinibs (mTOR and PI3K dual inhib itors) failed to selectively inhibit either signalling moiety 18 , but newer molecular inhibitors (mTORC1 and mTORC2 dual inhibitors) exhibit greater potency for mTOR 19 . These agents are being investigated for the treatment of malignancy in phase I and II clinical trials 20 but have yet to be tested in clinical organ transplantation.
mTOR in renal physiology
Given the ubiquitous expression of mTORC1 and mTORC2 in the kidney, elucidating the roles of mTOR in renal physiology is a formidable task. Nonetheless, phar macologic inhibition and targeted cellspecific genetic deletion have enabled analyses of mTOR function in the rodent and human kidney (FIG. 2) . Studies of patients with TSC, a syndrome with autosomal dominant inheri tance characterized by upregulation of mTORC1, have also increased understanding of the consequences of enhanced mTORC1 activity on renal physiology. Although much of the current understanding of mTOR function pertains to the podocyte or tubular epithelial cell, renal endothelial and immune cells are emerging as important players in the regulation of renal homeostasis and metabolism.
Podocytes
Glomerular podocytes are highly differentiated, volu minous cells with numerous foot processes that line the outer aspects of the glomerular basement membrane (GBM). The foot processes interdigitate with each other and form the slit diaphragm, an intercellular junction composed of several membrane proteins that regulate protein movement into the urinary space 21 . Although glomerular diseases can be caused by disturbances in various barrier components, podocyte loss and
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• The mTOR pathway has a central role in the regulation of cell metabolism, growth and proliferation • Pharmacological inhibition of mTOR and selective gene targeting of mTORC1 or mTORC2 in podocytes and tubular epithelial cells has helped to elucidate their role in renal cell homeostasis, including in autophagy • Mechanistic insights into the roles of mTOR complexes in regulating immune cell function are helping to improve understanding of the effects of mTOR inhibitors in renal disease and transplant rejection • mTOR is increasingly recognized as having a fundamental role in the development of glomerular disease and in acute kidney injury; its role in fibrotic kidney disease is less certain • New generation dual mTORC1 and mTORC2 inhibitors offer potential for the treatment of renal cell carcinoma • mTOR inhibitors are associated with reduced rates of skin cancer and cytomegalovirus infection in renal transplant recipients effacement is a critical event that, if not constrained, leads to proteinuria, renal fibrosis and endstage renal disease (ESRD). Much of the understanding of podocyte mTORC1 and mTORC2 function stems from genetic deletion studies. In mice, podocytespecific embryonic knock out of mTORC1 (owing to deletion of the regulatory associated protein of mTOR (Raptor)) resulted in early albuminuria, later development of glomerulosclerosis, weight loss and increased mortality 22 . Loss of podo cyte mTORC1 in adult mice failed to induce similar deleterious effects. Surprisingly, heterozygous deletion of Raptor in podocytes rescued glomerular expression of phosphory lated S6 kinase (pS6; a marker of mTORC1 activity) and podocyte volume. Mice with podocyte specific loss of mTORC2 (owing to deletion of rapamycin nsensitive companion of mTOR (Rictor)) did not exhibit significant phenotypic differences compared to littermate controls, with the exception of transient albuminuria fol lowing protein overload. However, combined deletion of both mTOR complexes from podocytes precipitated an early (6 weeks of age) fulminant proteinuric pheno type, suggesting some degree of interaction between mTORC1 and mTORC2 in the regulation of podocyte development and homeostasis.
Excessive mTORC1 activity can also result in severe pathologic effects, including hallmarks of diabetic nephropathy. In a murine study, podocytespecific dele tion of Tsc1 led to aberrant mTORC1 activation, enhanced pS6 expression, mesangial expansion, GBM thickening, podocyte loss, podocyte footprocess effacement and proteinuria (that was attenuated by rapamycin), as well as glomerular expression of transforming growth fac tor β1 (TGFβ1), type IV collagen and fibronectin 23 . 
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The remaining podocytes of the transgenic mice had a fibroblastic phenotype with markers of endoplasmic retic ulum stress. Immunofluorescence studies demonstrated altered distribution of podocyte nephrin and synaptopodin that was corrected by rapamycin administration.
Tubular epithelial cells
Tubular epithelial cells (TECs) are bathed in urine via their apical membranes and have an important role in maintaining salt and water balance, typically via their basolateral surfaces. This role is accomplished largely via Figure 2 | Roles of mTOR complexes in the kidney. mTOR complexes (mTORCs) are expressed throughout the nephron and regulate homeostasis of all resident parenchymal and non-parenchymal cells. Disruption of mTOR signalling results in various pathologies that are dependent on cellular location and whether mTORC1 or mTORC2 is targeted. In response to mTOR inhibition, proximal tubular epithelial cells downregulate megalin resulting in proteinuria, whereas inhibition of mTOR in distal tubular epithelial cells leads to polyuria, natriuresis and a reduction in inflammatory cell infiltrate and fibroblastic responses following ischaemia-reperfusion injury (IRI). In the glomerulus, mTOR inhibition disrupts podocyte function leading to proteinuria and glomerulosclerosis, whereas endothelial cell proliferation is limited. Ab, antibody; ENaC, epithelial sodium channel; ERK, extracellular signal-regulated kinase; GLUT-12, glucose transporter type 12; NKCC2, Na-K-Cl co-transporter 2; SGK1, serum and glucocorticoid inducible kinase 1; S6RP, S6 ribosomal protein.
energydependent cellular transporters. Initial evidence that mTOR might regulate tubular homeostasis came from repeated observations of electrolyte disturbances in renal transplant recipients treated with rapamycin, although the underlying cause of these disturbances is still disputed. The renalrelated adverse effects of rapa mycin are typically hypokalaemia 24 , hypomagnesae mia and hypophosphataemia 25, 26 , as well as decreased urinary calcium excretion 27 . Sirolimus decreases the expression of the apical Na-K-2Cl cotransporter (NKCC2) in the thick ascending limb (TAL), result ing in renal tubular wasting of sodium, magnesium and potassium 26 . The phosphaturic actions of rapa mycin might be linked to the induction of klotho, Rictor and mTORC2, which has been shown in vivo and in an immortalized renal tubular cell line 28 . Post transplantation phosphaturia is aggravated by admin istration of sirolimus, although this effect is reportedly not the result of altered phosphate uptake via sodiumphosphate cotransporters in the brush border of the proximal tubule 29 . Nevertheless, in Xenopus oocytes expressing sodium-phosphate transporters, co transfection with mTOR increased phosphate currents and this effect was abrogated by exposure to rapamy cin 30 . The reasons for these conflicting findings are unclear and further work is needed to elucidate the role of mTOR inhibition in phosphaturia.
The past few years have seen several reports linking mTORC1 to proximal tubular transport mechanisms. Work performed mainly in Drosophila melanogaster showed that the proton pump VATPase responsible for intracellular compartment acidification and apical amino acid uptake requires mTORC1. This interplay seems to be regulated through the multiligandbinding receptor megalin 31 . Indeed, in C57BL/6 mice, longterm rapamycin exposure reduced proximal tubular megalin expression and caused concurrent low molecular weight proteinuria, consistent with renal proximal TEC dys function. A subsequent study demonstrated that mice deficient in proximal tubular mTORC1 present with a Fanconi Syndromelike phenotype, consisting of phos phaturia, glucosuria, lowmolecular weight proteinu ria, albuminuria and aminoaciduria 32 . Deep proteomic and phosphoproteomic analysis showed that mTORC1 deficiency affects the translation and phosphorylation of specific transport proteins, regulators of transcellu lar transport, and proteins involved in endocytosis in a kinasedependent manner. In contrast to the earlier study in Drosophila 31 , no alterations in the abundance of the two scavenger receptors cubilin and megalin could be detected.
In mice, specific deletion of Raptor (mTORC1) in distal TECs did not cause significant developmen tal defects, but these animals developed polyuria and hypercalciuria after weaning as a result of a defect in TAL countercurrent multiplication 33 . Consistent with these perturbations, transcriptional profiling identified reduced levels of NKCC2 in these mice. Generation of mTORC1/2deficient animals resulted in aggravated pathology and increased mortality, suggesting that these complexes have complimentary roles.
Although the molecular pathways downstream of mTORC1 and mTORC2 that regulate ion channels in the TAL (such as NKCC2) remain to be determined, consid erable advances have been made in the understanding of how mTOR regulates the aldosteronesensitive epithelial sodium channel (ENaC), a protein that is most abundant in the distal tubule. Serum and glucocorticoid inducible kinase 1 (SGK1) acts as a central driver of this process by increasing cell surface expression of ENaC via inhibi tion of the E3 ubiquitinprotein ligase Nedd42 (REF. 34 ) and mTORC2 has been found to activate SGK1 via phosphorylation of its hydrophobic motif 35 .
To investigate the physiological relevance of the mTORC2-SGK1-ENaC axis in vivo, researchers com pared the effect on electrolyte homeostasis of targeting mTORC1 (using rapamycin) with that of dual inhibition of mTORC1 and mTORC2 (using the TORKinibs PP242 and AZD8055) 36 . Interestingly, the TORKinibs uniquely induced polyuria and substantial natriuresis without kaliuresis (compared to rapamycin) in wildtype mice. This effect was lost, however, when PP242 and the ENaC blocker amiloride were administered together, suggest ing that the natriuretic effects of TORKinibs occur upstream of the ENaC.
Conflicting data came from a study that used a mouse genetic approach to examine the role of mTORC2 in the aldosteronesensitive distal nephron 37 . In contrast to the findings of the subtractive pharmacological inhib itor experiments, mice with mTORC2 deficiency (as a result of Rictor deletion) developed lifethreatening hyperkalaemia when challenged with a high K + diet or the K + sparing diuretic triamterene. Patchclamp record ings of cortical collecting ducts revealed an absence of bariumsensitive K + currents. Phosphorylation of the hydrophobic motif of SGK1 and PKCα was virtually absent and membrane expression of renal outer med ullary K + channels was greatly reduced in the Rictor deficient animals. These findings demonstrate that mTORC2 drives kaliuresis and is not an essential pre requisite for Na reabsorption. The assumption that the effect of a TORKinib minus the effect of rapa mycin will equal a mTORC2specific effect might be too sim plistic. To obtain true insight into mTORC2specific effects in the absence of mTORC2 inhibitors, a genetic approach seems to be required, underlining the necessity to combine genetic deletion and pharmacological inhi bition approaches for a full appraisal of the functional importance of mTOR complexes.
Renal endothelial cells
Diseases such as thrombocytopaenic purpura (TTP), haemolytic uraemic syndrome (HUS), preeclampsia, antiphospholipid antibody syndrome (APS) and antibodymediated kidney allograft rejection are driven partially by endothelial cell activation and injury. Conceptualizing mTOR as a driver of vascu lar endothelial proliferation and immune activation has developed over the past 10 years. Activation of the mTORC pathway has been observed in the intra renal vessels of patients with APS nephropathy 38 . Immunofluorescent staining of endothelium from the renal vessels of individuals with primary or secondary APS identified phosphorylation of S6 ribosomal protein (S6RP, indicating mTORC1 acti vation) and Akt (indicating mTORC2 activation) 38 , often with colocalization. Incubation of human microvascular endothelial cells with antiphospho lipid antibody led to upregulation of S6RP and Akt phosphory lation in vitro, a phenomenon that was prevented by treatment with the TORKinib PP242. Interestingly, patients who received sirolimus after transplantation showed reduced vascular prolifera tion and lesion recurrence on biopsy, compared to those receiving alternative immunosuppression. Use of mTOR inhibitors was also associated with a higher incidence of functioning allografts up to 12 years posttransplantation.
The development of transplant vasculopathy is induced by antibody binding to HLA class I molecules expressed by endothelial and smooth muscle cells, which promotes their proliferation. The effect of these anti bodies on endothelial cell proliferation has been veri fied in vitro and is mediated by formation of mTORC1 and mTORC2 (REF. 39 ). Downregulation of endothelial mTOR using small interfering RNA (siRNA) against Rictor or Raptor blocked HLA class I antibodyinduced endothelial cell proliferation, whereas administration of rapamycin prevented HLA class I antibodyinduced Akt phosphorylation. Additional studies have demonstrated TORC2mediated extracellular kinase (ERK) phos phorylation induced by endothelial cellbased MHC class I and integrin ligation 40 , which was inhibited by rapamycin.
Although the role of mTOR in endothelial cell pro liferation might imply a benefit of mTOR inhibitors in kidney transplant recipients, these agents have also been implicated in the development of donorspecific anti bodies (DSAs) that might precipitate antibodymediated rejection (ABMR). Both sirolimus 41 and everolimus 42 are associated with the development of de novo DSAs and subsequent onset of ABMR 42, 43 . Although endothelial mTOR pathway activation has been implicated in acute and chronic ABMR in rodent and human studies 20, 39, 44, 45 , the therapeutic efficacy of mTOR inhibitors in these set tings remains unclear. Potential explanations for these conflicting findings might include reduced potency of mTOR inhibitors, compared to CNIs, for T cell subsets that regulate ABMR, and higher rates of intolerable adverse effects with mTOR inhibitors that might limit compliance and, as a consequence, increase allograft rejection.
Regulation of autophagy
Autophagy is a catabolic process that degrades var ious substrates including misfolded proteins, dam aged organelles and microorganisms. This material is sequestered in autophagosomes before breakdown in lysosomes. In most circumstances autophagy promotes cell survival and is important when a cell faces envi ronmental stress and must use cellular components as an energy source 46 . By contrast, the mTOR path way is most active in nutrientreplete environments.
Thus, autophagy and mTOR can be envisaged as opposing molecular pathways that negatively regulate each other.
Importantly, mechanisms by which mTOR regu lates autophagy have been described in the past dec ade. Three groups have demonstrated that mTORC1 inhibits the UNC51like autophagyactivating kinase (ULK) complex by phosphorylating ULK1/2 and other components [47] [48] [49] . In mammalian cells phosphorylation of ULK1/2 at Ser758 by mTORC1 prevents ULK1/2 activation by the energy sensor AMPactivated pro tein kinase (AMPK). mTORC1 has also been found to regulate autophagy at the transcriptional level via phosphorylation and cytoplasmic sequestration of transcription factor EB (a regulator of lysosomal and autophagy genes) and by inhibition of PI3K catalytic subunit type 3 (also known as VPS34), which has an important role in autophagosome formation 46 . Whether mTORC2 regulates autophagy directly, independent of mTORC1, remains unclear.
Given the high metabolic demands and autophagic flux that exist in podocytes and TECs, the role of auto phagy in renal health and disease is now under investi gation 50 . In ageing mice, podocytespecific deletion of the autophagy inducer, autophagy protein 5 (Atg5), led to the accumulation of oxidized protein, podocyte loss, proteinuria and glomerulosclerosis 51 . Similarly deletion of Atg5 from the renal epithelial cells (tubules and podo cytes) of mice resulted in the development of a disease phenotype resembling human focal segmental glomer ulosclerosis (FSGS) by the age of 2-4 months 52 . Thus, the concept of 'autophagic failure' has become an attrac tive hypothesis to explain podocytopathies in humans. Renoprotective effects of autophagy in AKI have also been characterized 53 . Nonetheless, the beneficial effects of enhanced autophagy induced by mTOR inhibitors are likely to be offset by detrimental effects of these agents on cell growth and survival.
Renal ageing
Regulation of ageing by mTOR was first noted in studies of Saccharomyces cerevisiae 54 , Caenorhabditis elegans 55 and D. melanogaster 56 . A subsequent report showed that feeding aged mice with rapamycin extended their lifespan 57 . The role of mTOR in ageing has been reviewed previously 58 . Agerelated alterations in the kidney include accumulation of lipofuscin, damaged mitochon dria and protein aggregates, as well as loss of podocytes and autophagosome formation. Atg5, a component of the autophagic pathway regulated by mTOR, is critical for autophagosome creation, and its deletion in specific renal compartments (podocytes or proximal tubules) phenocopies findings seen in aged kidneys 51, 53 . Studies in ageing rodent kidneys have shown elevated mTOR expression in whole tissue and in isolated primary mesangial cells 59 , possibly through regulation of cell cycling by p21 and/or the class III histone deacetylase sirtuin 60 . These features are ameliorated, at least in vitro, by treatment with rapamycin. Whether direct manipu lation of renal mTOR expression and signal transduction ameliorates features of renal ageing remains to be shown. 62, 63 . Both innate (dendritic cells (DCs) and macrophages) and adaptive immune cells (T and B lymphocytes) reside in the kid ney and can promote AKI and chronic kidney disease (CKD) [64] [65] [66] , but their dependence on mTOR activity remains unexplored. Our understanding of the role of mTOR in renal immunity must therefore be extrapolated largely from studies of lymphoid tissue. These observa tions (FIG. 3; TABLE 1) provide insight into the potential of rapalogues, TORKinibs and other PI3K-mTOR path way inhibitors in transplantation. In parallel, studies in experi mental organ transplantation using rodent and non human primate models, have increased understanding of the complex effects of rapamycin on allograft function.
Dendritic cells
DCs are professional antigen presenting cells that link the innate and adaptive immune responses by regulating Tcell responses to antigen. In the context of transplantation, they orchestrate both direct and indirect allorecognition. DC density in biopsy samples has been reported to correlate with Tcell proliferation and diminished graft survival in human kidney trans plantation 67 . The understanding of the role of mTOR in shaping DC function stems largely from studies of the influence of rapamycin on these cells 3, 61 . Protracted mTORC1 inhibition by rapamycin inhibits matura tion of DCs and their ability to promote effector Tcell proliferation, while promoting regulatory T (T reg ) cell enrichment 68, 69 . In a rodent heart transplant model, rapamycintreated DCs promoted allograft survival following their systemic administration. Paradoxically however, exposure to rapamycin can also enhance the Tcell stimulatory function of DCs with enhanced IL12p40/p70 production following lipopolysaccharide stimulation 70 . Evidence for an immunostimulatory effect of rapamycin on DC function also stems from studies of therapeutic vaccination. Pulsing DCs in vitro with a combination of rapamycin and Tolllike receptor (TLR) agonists enhanced antigenspecific CD8 + Tcell responses and antitumour immunity, as well as pro longed DC survival 71 . Whether these effects are medi ated by mTORC1 or mTORC2 remains unclear, but both genetic deletion and RNA targeting of mTORC2 (Rictor) in DCs induces a hyperinflammatory pheno type 72, 73 and promotes alloreactive type 1 T helper (T H 1) and T H 17 responses in vitro and in vivo, sug gesting that the effects may be mediated by mTORC2 (REF. 74 ).
T cells
The transition from naive to effector T cells in response to antigen stimulation involves a metabolic switch from primarily oxidative phosphorylation to a more glyco lytic pathway 75 . This switch enables activated T cells to consume large amounts of glucose and glutamine and undergo rapid proliferation and growth. By contrast, T reg cells, memory T cells and T follicular helper cells (Tfh; a T cell subset that stimulates germinal centre B cells) engage metabolism differently with a pro pensity to oxidize fatty acids and suppress mTOR through AMPK.
As understanding of T cell metabolism has pro gressed, distinct roles of mTORC1 and mTORC2 in the development of T cell subsets have also emerged. In mice, both mTORC1 and mTORC2 promote thymic Tcell development 76 . Administration of rapamycin promotes thymic atrophy, accelerates apoptosis of T reg cells 77 . The 'sparing' of T reg cells exposed to mTOR inhibitors has been observed in vivo, in mice and in the peripheral blood of kidney transplant recipients, and might be explained by the differing metabolism of these cells compared to that of effector T cells 78, 79 . Paradoxically, specific deletion of mTORC1 (Raptor) in T reg cells results in loss of suppressive activity and fatal inflammation in vivo 80 . These results suggest that a basal level of mTOR activity, which might be 68, 70 , suppresses inflammation (mTORC2) 72, 283 and restrains T-cell responses in human myeloid DCs (mTORC1) 284, 285 May either promote (ACR) or restrain (pneumonitis) immune hyper-responsiveness
Plasmacytoid DCs
Promotes activation (TLR9) and type-I IFN production; restrains (TLR7) Tmem cell and T reg cell proliferation 286, 287 May regulate function including interaction with T reg cells Effector T cells Drives T H 1 (mTORC1), T H 2 (mTORC2 +/-mTORC1), and T H 17 (mTORC1) cell differentiation and growth 81, 82, 288 Promotes expansion with role in rejection (ACR, acute and chronic ABMR)
Follicular helper CD4 T cells
Restrains differentiation (mTORC1) 83 May prevent alloantibody formation and ABMR
CD8 memory T cells
Restrains anti-viral and anti-tumour immunity 124, 126, 289 May promote viral infections, including CMV, human herpesvirus 8 and BK virus 127, 290 T reg cells Promotes homeostasis and function (mTORC1) 80 , limits expansion (mTORC1 +/-mTORC2) 79 May restrict role in promotion of tolerance
Neutrophils
Formation of neutrophil extracellular traps 291 , promotes endothelial cell and extracellular matrix adhesion (mTORC1) 292 , promotes chemotaxis (mTORC2) 293, 294 May promote role in rejection (ACR, acute and chronic ABMR) 83 . These results are relevant to renal transplantation as they could account for the elevations in DSA levels seen in some kidney transplant recipients on rapamycin.
B cells
Everolimus is a potent inhibitor of human Bcell activation and function (that is, Tcelldependent immunoglobulin production) 84 . Marginal zone (MZ) B cells and humoral immune responses are also affected by mTOR manip ulation. Thus, conditional deletion of TSC1 in murine B cells leads to loss of MZ B cells 85 , whereas conditional deletion of Rictor (mTORC2) impairs Bcell survival and antibody responses 86 . On the other hand, two studies that used mTOR inhibitors to dissect the role of mTOR in anti body class switching have produced conflicting results. In mice rapamycin administration promoted crossstrain protection against lethal influenza infection by inhibit ing Bcell class switching 87 , whereas transient treatment with TORKinibs increased titres of classswitched high affinity antibodies to a hapten-protein conjugate 88 . Given these results, coupled with clinical data on the relation ship between mTOR inhibitors and DSA production, more basic and clinical studies are necessary to ascer tain whether mTOR pathway manipulation protects or promotes ABMR. Data suggest that everolimus inhibits antiHLA class I antibodymediated endothelial cell sig nalling, migration and proliferation more potently than does sirolimus 89 , pointing to a potential beneficial effect of everolimus in the prevention of chronic ABMR.
NK cells and NKT cells
Studies of the role of mTOR in natural killer (NK) cells and NKT cells have extended our understanding of mTOR immunobiology. Given the important roles of these cells in DSA formation and chronic ABMR, insights from these studies have direct implications for kidney transplant rejection.
mTOR is an essential component of the IL15 sig nalling pathway in NK cells and drives both their devel opment in the bone marrow and their activation in the periphery 90 . However, only minimal effects of mTOR inhibition on antiHLA antibodydependent NK cell activation have been reported 91 . On the other hand, exposure to either rapamycin or the dual mTORC1 and mTORC2 inhibitor PP242 inhibits inflammation induced priming of induced (i)NK cells. Genetic deletion of either mTORC1 or mTORC2 in iNKT cells indicates that these complexes have important, nonoverlapping roles. While mTORC2 is essential for transition of iNKT cells from stage 1 to 2 development in the thymus, stage 3 thymicresident iNKT cell subsets depend more on mTORC1 for survival 92 .
mTOR inhibitors in transplantation Experimental organ transplantation
The majority of studies investigating mTOR in experimental organ transplantation have involved administration of rapamycin, either alone or in com bination with other agents. Initially, rapamycin mono therapy was shown to prolong organ allograft survival in rodents 93, 94 . Importantly, administration of rapa mycin late posttransplantation halted the progression of allograft vasculopathy in rats and nonhuman pri mates 95, 96 . Attributes of rapamycin reported in murine and NHP transplant models include an ability to induce myeloidderived suppressor cells, preserve T reg halflife and phenotype postinfusion, and produce mixed chimerism when combined with costimulation blockade 97, 98 . New generation mTOR inhibitors are of considerable interest in transplant models. TORKinibs were devel oped initially to overcome the limitations of rapamycin in clinical oncology. Thus 'rapalogue resistance' , seen in a variety of tumours treated with rapalogues, is largely attributed to incomplete inhibition of mTORC1 and compensatory activation of mTORC2. Despite rapid incorporation of these drugs into early phase clinical trials in oncology, little is known about their efficacy in transplantation. Theoretical advantages of TORKinbs over rapamycin in this setting include greater inhibi tion of mTORC2 in Tfh cells, B cells and endothelial cells, all of which orchestrate both DSA formation and chronic allograft vasculopathy. The dual mTOR inhib itor INK128 regulates NFκB signalling and suppresses inflammatory cytokines in a murine macrophage cell line (RAW 264.7) 99 . Moreover, the ATPcompetitive mTOR inhibitor AZD8055 was shown to prevent acute rejection of mouse heart allografts and increase the num bers of graftinfiltrating T reg cells 100 . In a rat transplanta tion model, modulation of both mTORC1 and mTORC2 eliminated chronic rejection when combined with subtherapeutic ciclosporin 101 . These data, coupled with the unacceptably high rates of late renal allograft failure secondary to chronic ABMR and vasculopathy, provide justification for further investigation of novel mTOR pathway inhibitors in transplantation.
Clinical organ transplantation
Initial studies that combined sirolimus (versus placebo or titrated dosage 102 ) with ciclosporin and prednisolone in renal transplantation demonstrated lower biopsy proven acute rejection (BPAR) with the sirolimus com bination therapies than with ciclosporin and prednisone alone 103, 104 , even in the context of reduced ciclosporin dosage 104 . Sirolimus was also clearly superior to aza thioprine 105 and has been investigated as a possible • 1 year: higher GFR, higher BPAR, lipidaemia and proteinuria, lower haemoglobin and greater adverse events in EVL group • 5 years: higher GFR in EVL group, no effect of higher BPAR (grade I) on long-term graft function, no between-group differences in graft loss, mortality, adverse events and neoplasm calcineurinsparing agent 24, 106 . A subsequent study, how ever, found a higher rate of BPAR in patients on prednisone and sirolimus who withdrew ciclosporin at 3 months post transplantation compared to those who remained on this agent 107 . Furthermore, in the EliteSymphony study 108 , patients assigned to sirolimus, mycophenolate mofetil and prednisone had higher rates of BPAR (37.2%) than those treated with either low dose ciclosporin (24%) or tacrolimus (12.3%). These findings demonstrate that use of sirolimus as baseline immunosuppression in the absence of a calcineurin inhibitor (CNI) has limitations, including higher rates of acute rejection 108, 109 , albeit offset by better glomerular filtration rate (GFR) 107 . The majority of studies and metaanalyses show that patientbased outcomes and the incidence of treatment withdrawal are worse following mTOR inhibition with sirolimus or everolimus compared to CNIbased regimens [110] [111] [112] . mTOR inhibitors are generally accepted to provide inferior initial post transplantation immunosuppression than conven tional CNIbased regimens. In addition, the propensity of mTOR inhibitors to impair wound healing, induce wound dehiscence and promote lymphocele develop ment further precludes their use as a primary immuno suppressant. mTOR inhibitors might be best utilized for conversion therapy to avoid CNI toxicity, or to pro vide flexibility for patients who develop CNIrelated complications. The documented adverse effects associ ated with mTOR inhibitors include bone marrow sup pression, hypertriglyceridaemia, peripheral oedema, gastrointestional disturbance and stomatitis, new onset diabetes after transplantation, protein uria, gonadal toxicity, cough, dyspnoea and interstitial pneu monitis 113 . The angiotensinconvertingenzyme (ACE) inhibitor ramipril has proven effective in reducing the incidence of proteinuria for up to 1 year after con version to sirolimus in renal transplant recipients on maintenance immunosuppression 114 . However, the underlying pathobiology contributing to these adverse effects is incompletely understood. The development of aphthous ulcers might represent a breach of mucosal immunity and a lack of CD4 + CD25 + T reg cells 115 , but this mechanism is counterintuitive as treatment with mTOR inhibitors tends to spare T reg cells from deple tion in preclinical models and human kidney graft recipients 116 . Impaired wound healing through inhi bition of cell proliferation and neoangiogenesis, or impaired glucose tolerance might be contributing fac tors. Similarly, interstitial pneumonitis might have an immunological aetiology, with increased CD4 + T cells found in bronchoalveolar lavage 117 . Since the FDA approval of rapamycin (sirolimus) for use in clinical kidney transplantation in 1999, an extensive literature has emerged on its effects on graft survival, mortality and other important clinical out comes, such as malignancy, cardiovascular disease and infection. The majority of studies of mTOR inhibitors involve conversion from CNI either early (2-6 months) or late (>6 months) posttransplantation. Few studies on the de novo use of mTOR inhibitors and mTOR inhibi tor monotherapy post kidney transplantation have been conducted (TABLE 2) .
In the majority of the conversion trials published to date, mTOR inhibition has been compared with ciclo sporin. In one study of renal transplant recipients, a ciclosporinfree regimen based on sirolimus reduced aor tic stiffness, plasma endothelin1 and oxidative stress, sug gesting a protective effect on the arterial wall that might . On the other hand, among patients randomly assigned to either sirolimus or ciclosporin at 3months post transplantation, the incidence of subclinical inflammation in protocol biopsy samples 1 year posttransplantation was greater in the sirolimus group 119 . Tacrolimus is currently the most commonly used CNI in kidney transplantation. In a prospective rand omized trial, kidney transplant recipients receiving rapid cortico steroid withdrawal, tacrolimus and mycophenolate mofetil (MMF) for 1 month were randomly assigned to receive either sirolimus plus MMF or tacrolimus plus MMF maintenance therapy 120 . Although graft survival at 2 years was similar between the groups, withdrawal from the study owing to rejection or adverse effects was a major problem in the sirolimus group (63% versus 18% in the tacrolimus group). These data indicate that in the absence of steroids, sirolimus and tacrolimus are not interchange able. Most studies comparing tacrolimus and sirolimus have involved de novo use of these agents rather than conversion 108, 109, 121 . Other than their antineoplastic effects, a theoretical advantage of mTOR inhibitors in transplantation lies in their antiviral properties. mTOR inhibitors stimulate cytomegalovirus (CMV)specific T H 1 cells and γδ T cells, and translation of CMV viral proteins relies on host mTOR activity [122] [123] [124] . Furthermore, sirolimus inhibits and tacrolimus activates BK polyomavirus replication in renal TECs 125 . Despite these paradoxical antiviral properties, exposure to rapamycin enhances the quality and quantity of pathogenspecific but not graftreactive CD8 + T cells 126 . As BK and CMV infections cause con siderable excess morbidity and mortality, the immuno modulatory effects of these mTOR inhibitors provide a rationale for conversion from CNIs posttransplantation. Unfortunately, many studies have not been adequately powered to compare the influence of different immuno suppressive regimens on the incidence of either CMV or BK virus infection. Nonetheless, many comparative studies have demonstrated that early use of mTOR inhib itorbased regimens can reduce the incidence of CMV infection 127, 128 . In a single centre case series that included 15 patients with BK nephropathy, suspension of myco phenolate and conversion from tacrolimus to everolimus immunotherapy was associated with decreased viraemia and increased graft survival 129 . Although a role for mTOR inhibitors in biopsyproven BK nephropathy is plausi ble, prospective large randomized studies are needed to adequately address this question.
Overall, mTOR inhibitors have some attractive char acteristics, particularly their beneficial effects on kidney function by enabling CNI sparing and their association with reduced rates of malignancies and nonmelanoma skin cancer 130 , fewer viral infections and reduced weight gain 131 compared to CNIbased regimens 132 . Nonetheless, for the many renal transplant recipients with a documented history of sensitization, these agents remain inferior to CNIs. For these reasons, coupled with adverse effects and the availability of antiviral agents, mTOR inhibitors are currently not used extensively posttransplantation. As malignancy and infection remain two of the most common causes of death among kidney transplant recipients, estab lishing novel and less toxic ways to manipulate the mTOR pathway is an important goal in transplantation. mTOR in AKI and ischaemic injury AKI is an important health problem that affects approx imately one in five adults and one in three children who are hospitalized 133 . As well as increasing morbidity and mortality in the acute setting, AKI increases the long term risk of developing CKD 134 . The underlying aeti ologies that precipitate AKI are numerous and can be categorized into prerenal, intrarenal and postrenal causes 135 . When adequately addressed, prerenal and postrenal AKI resolve rapidly. Management of intra renal AKI is more difficult; this disease is often the result of ischaemic or toxic injury to renal tubules, which typi cally requires days to weeks to resolve. A special situation arises during kidney transplantation in which donated organs inevitably undergo both cold and warm ischae mia. Indeed, the potential positive and negative seque lae of mTOR inhibitor therapy first became evident in renal allograft recipients [136] [137] [138] . Findings of delayed graft function (DGF) and cast nephropathy in patients treated with rapamycin suggest that this therapy exerts increased toxicity on TECs and/or retards healing after ischaemic injury 136 . In all prospective randomized trials published to date, however, no association between rapamycin therapy and a reduction in GFR has been reported, sug gesting that the drug does not have a nephrotoxic effect, at least in the longterm. To further elucidate the effects of mTOR inhibitors on TECs and vascular endothelial cells, as well as on local and systemic immune cells, rodent models of ischaemia-reperfusion (I/R) and various renal transplant models have been used.
Although several lines of evidence initially pointed to aggravation and delayed recovery from renal I/R injury with rapamycin 139, 140 , this finding was later chal lenged 141, 142 . The three most probable confounders con tributing to these contradictory findings were likely the control group selected, the time of mTOR inhibitor administration and the timing of the analysis 141, 143 . Most studies that used a placebo group have reported adverse outcomes after administration of mTOR inhibitor 140, 144 . This delayed functional recovery could be reproduced in a mouse model by conditional deletion of mTORC1 in tubular cells before inflicting I/R injury 33 . By contrast, studies that have compared mTORC1 inhibitors to CNIs have reported beneficial outcomes of mTOR inhibition that can be explained mainly as the result of avoiding the deleterious effects of ciclosporin on the renal micro circulation 141, 145 . Moreover, a preconditioninglike effect of mTOR inhibition before transplantation has been observed in organs such as the heart 146 . This effect has also been reported in experimental renal transplantation; treatment of the donor with a single dose of rapamycin before nephrectomy improved allograft function 147 . Another important confounder in studies of mTOR inhibitors in AKI is the timing of analysis after I/R. Studies that reported an adverse outcome of mTOR inhibition investigated early time points (within several days of transplantation), whereas those that analysed much later time points (up to 16 weeks following the ini tial I/R) reported beneficial effects in normotensive rats and to a lesser degree in hypertensive animals 139, 145, 148, 149 . Unfortunately, only a few studies have explored the mechanisms that underlie the observed effects. While reduced proliferation and increased apoptosis are sug gested as the most likely underlying cause of the initial adverse effects in I/R 33 directly linked to the role of the mTOR kinase, secondary effects of mTOR inhibition that influence dependent pathways (such as autophagy) or effects on the antioxidative system might be responsible for late beneficial effects of mTOR inhibitors in I/R 150, 151 . Few studies have investigated the role of mTOR in AKI unrelated to transplantation. Interestingly, AKI concurrent with the start of mTOR inhibitor therapy has been noted in patients with cancer, in whom it can present as an acutetubularnecrosistype injury 152 . By contrast, mTOR inhibition was found to be beneficial in a mouse model of AKI induced by HIVassociated nephropathy 153 . This effect was most likely mediated by downregulation of mTORinduced p53 expression resulting in a reduction in oxidative cell injury. Hence in this model, reduced apoptosis provided a functional and histological benefit.
In summary, the risk of delayed graft function seems to be increased in patients who are treated with mTOR inhibitors directly after transplantation. As this risk might complicate the immediate posttransplantation phase with regard to the need for additional dialysis and graft biopsy to exclude acute rejection in the context of delayed graft function, early treatment with mTOR inhibitors should be avoided. Most injury mechanisms seem to be related to the antiproliferative and pro apoptotic effects of mTOR inhibitors on the renal epi thelium, whereas specific effects on local and systemic immune cells that might affect the development of AKI have not been thoroughly explored.
mTOR in glomerular disease
The glomerulus regulates filtration by size and charge. Changes in glomerular permeability owing to hyper glycaemia 154 , induction of reactive oxygen species 155 or pharmacologic challenge 156, 157 underpin a number of disease processes. Exposure of healthy rats to an mTOR inhibitor (temsirolimus) increased early glomerular per meability, but reduced late permeability 158 . In BALB/c mice without renal pathology, rapamycin induced a mild deterioration in renal function, increased albu minuria and podocyte footprocess width, and induced a shortterm reduction in nephrin and podocin expres sion; these effects resolved after 8 weeks of treatment 159 . Although previous studies had demonstrated no gross histologic changes in the renal glomerulus in response to mTOR inhibition 160, 161 , pathologic abnormalities were seen in the rodent renal tubular compartment 162 and in vessels 163 . Glomerulonephritides comprise a substantial pro portion of human renal diseases and several rodent models have been developed to mimic these disorders. mTOR is increasingly recognized as having a fundamen tal role in the development of glomerular pathology, particularly in terms of dysregulation of rodent podocyte function 164 . Activation of mTORC1 in podocytes led to the development of glomerular crescents 165 , which was abolished following treatment with rapamycin. Podocyte homeostasis is disrupted by mTOR inhibitors (sirolimus and everolimus) that alter the cytoskeleton via RhoA signalling 166 , reduce vascular endothelial growth fac tor (VEGF) 167 synthesis and Akt phosphorylation 168 , downregulate the expression of nephrin 169 , podocin and synaptopodin 168 and affect cell motility. Additional studies have identified activation of Akt2 downstream of mTORC2 as critical for podocyte survival 170 .
Diabetes mellitus
Diabetes mellitus is a leading cause of CKD in developed countries and the causative aetiology of ESRD in 30-40% of patients seeking renal replacement therapy 171 . Early renal changes in response to hyperglycaemia include mesangial and glomerular basement membrane expan sion, glomerular hypertrophy and loss of capillary sur face area 172 . Diabetes is now thought to represent a state of mTORC1 hyperactivation 173 . The molecular mecha nism underlying compensatory hypertrophy is not well characterized, but involves increased phosphorylation of 40S ribosomal protein (rpS6), downstream of S6 kinase 1 (S6K1) 174 . This kinase in turn regulates protein synthesis and cellular growth downstream of mTORC1.
The role of pS6 as a molecular signature of mTORC1 activation in podocytes has been confirmed in the glo meruli of patients 22 and mice 23 with diabetes. Moreover, knockout of S6K1 protected against the development of renal hypertrophy in diabetic mice 23 . Inhibition of mTOR signalling has also been shown to ameliorate some renal compensatory mechanisms following the induction of diabetes. In mice with streptozotocininduced diabetes, renal hypertrophy was accompanied by upregulation of S6K1 kinase expression that could be attenuated by daily rapamycin administration 175 . Similarly in diabetic rats, rapamycin ameliorated albuminuria (but had no effect on glomerular hypertrophy) and downregulated the expression of mTOR, phosphory lated Akt, TGFβ1 and connective tissue growth factor 176 . These effects occurred without normalization of serum glucose and blood pressure levels and paralleled achievement of nor moglycaemia 177 . High glucose levels have been shown to induce podocyte apoptosis, activate mTOR and promote NADPH oxidase (Nox)1/4 expression; these effects are attenuated by rapamycin 178 .
Systemic lupus erythematosus
The chronic autoimmune disease systemic lupus ery thematosus (SLE) commonly affects the kidney through immune complex deposition, complement activation and infiltration of innate immune cells. MRL/lpr and female NZBW/F1 mice develop overt SLE and renal dis ease that can be mitigated by rapamycin treatment [179] [180] [181] [182] [183] . Activation of the P13K-Akt-mTOR pathway has been demonstrated in the affected glomeruli of NZBW/F1 mice, with upregulation of phosphorylated Akt (at res idues 308 and 473) and concurrent downregulation of podocin and nephrin. In the glomerulus, expression of mTOR and of phosphorylated mTOR (at Ser2448) is colocalized in podocytes and endothelial cells. Mice treated with rapamycin (either 1 week after develop ment of severe proteinuria or before SLE development) showed preservation of remaining renal mass and func tion, reduced levels of antidoublestrandedDNA anti bodies, mitigated pathognomonic histological lesions and maintenance of podocin and nephrin expression compared with untreated controls. Treatment with rapamycin or other mTOR inhibitors also suppressed interstitial inflammatory infiltrate (T cells, B cells and macrophages) in preclinical lupus models 179 . Despite the antiproliferative properties of rapamycin, few clin ical studies have used this agent to treat lupus nephri tis 184, 185 . Preliminary data showing improvements in serology, renal function and proteinuria with sirolimus in seven patients with this disease suggest that further investigation may be warranted 184 . (TABLE 3) . Moreover few studies have explored the mechanisms involving mTOR and glomerular pathophysiology, as well as beneficial effects related to mTOR inhibitors. Proteinuria is a key clinical feature of glomerular disease and urinary protein loss is regulated predominantly by podocytes 186 . Endoplasmic reticulum stress triggers the unfolded protein response, which is preceded by activa tion of mTORC1 and dysregulated energy production 187 ; both of these effects can be inhibited by everolimus administration.
General glomerulopathies
In rodents with adriamycin nephropathy, rapamycin reduces proteinuria, preserves renal function and ame liorates glomerulosclerosis and tubular dilatation, with reductions in the intrarenal expression of CC motif chemokine 5 (CCL5, also known as RANTES) and col lagen 188 . These renoprotective and antiproteinuric effects can be recapitulated with everolimus, which also restores glomerular nephrin and podocin expression 189 . Administration of everolimus slowed recovery from endothelial cell injury in a mouse model of thrombotic microangiopathy; this agent inhibited endothelial cell proliferation, but had no effect on endothelial cell apop tosis 190 . These data are in keeping with in vitro findings of dosedependent inhibition of glomerular endothelial cell proliferation. Everolimus also inhibits the expression of VEGF and S6K in cultured podocytes and in vivo.
The rat chronic Thy1.1 nephritis model (generated by injection of antibodies against glomerular mesan gial cells) mimics membranoproliferative glomerulo nephritis 191 . In this model, administration of everolimus, particularly at low doses, prevented compensatory glo merular hypertrophy, reduced fibronectin and VEGF expression and reduced renal influx of monocytic lineage cells 192 . Rapamycin similarly abrogated a rise in blood pressure attributable to CKD in these rats, but had a detrimental effect at high doses in the acute injury phase 193, 194 owing to inhibition of rat endothelial cell proliferation and glomerular neoangiogenesis 100, 101 . A deleterious effect of everolimus has also been reported in the rat remnant kidney model; this agent induced proteinuria, interstitial fibrosis and glomerulosclero sis 195 . In a rat model of established IgA nephropathy, lowdose rapamycin reduced IgA deposition, prevented progression of proteinuria and limited deterioration of renal function 196 . These effects correlated with cell cycle arrest, upregulation of cyclindependent kinase inhibitor 1B and presumably inhibition of mesangial cell proliferation.
In Heymann nephritis 197 -a rodent model of human membranous nephropathy -production of antibodies directed against the target antigens megalin and receptor associated protein 198 leads to the development of glomer ular deposits. Rapamycin mitigates proteinuria 199 and histologic lesions in this model 200 , including CD8 + T cell inflammation, with restoration of glomerular expres sion of podocin and nephrin 200 and a reduction in immunoglobulin deposits 199 .
A nephrotoxic serum nephritis model, induced by immunization with heterologous (sheep or rabbit) GBM proteins, is analogous to Goodpasture disease in humans. In this model the development of glomeru lar crescents is preceded by mTORC1 activation 201 . Rapamycin administration concurrent with disease ini tiation decreased proteinuria, inflammatory infiltrate and T H 1 cytokine production. By contrast, when com menced after disease induction 202, 203 , rapamycin treat ment led to increased albuminuria and accompanying macrophage and CD4 + T cell infiltration with increased Foxp3 transcripts suggesting accumulation of T reg cells, and glomerular proinflammatory cytokine production. These divergent, timedependent effects are thought to be related to an initial, beneficial, downregulation of T and B cell responses, followed by inhibition of podo cyte VEGFA production, which reduces endothelial proliferation and thus the integrity of the glomerulus.
Few clinical studies have investigated the influence of mTOR modulation in glomerular disease (TABLE 3) , possi bly owing to concern about exacerbation of proteinuria. Moreover, low numbers of recruited patients limit the interpretation and generalizability of existing studies. In 23 patients with poorprognosis IgA nephropathy (>1g proteinuria per 24 h and GFR 30-60 ml/min/1.73 m 2 ) treated with ACE inhibitor and a statin, who were also assigned sirolimus or placebo for 12 months 204 , those treated with sirolimus showed improvements in GFR and decreased endocapillary proliferation compared with the placebo group. Proteinuria, glomerulosclero sis and interstitial fibrosis were unchanged, regardless of treatment.
The efficacy of sirolimus has also been evaluated in 21 patients with FSGS 205 ; the therapy induced com plete remission in 19% of patients and partial remission in 38%, with maintenance of GFR and a reduction in proteinuria. A phase II openlabel trial in six patients with FSGS, however, reported a lack of responsiveness to sirolimus and an association of this therapy with nephrotoxicity 206 . In some kidney transplant recipients, highdose sirolimus has been reported to induce de novo FSGS, characterized by decreased expression of synaptopodin and p57 (REF. 207) . A case of successful treatment of min imal change nephropathy using combined tacrolimus and rapamycin has also been reported 208 . mTOR in polycystic kidney disease Autosomal dominant polycystic kidney disease (ADPKD), the most common renal monogenetic dis ease, is caused by mutations in PKD1 or PKD2 (REF. 209) . Although this disease primarily affects the kidneys, the liver, cerebral blood vessels, gut, pancreas and cardiac valves can also be affected; PKD is thus a systemic dis ease 210 . Approximately half of affected patients require renal replacement therapy in their sixth or seventh dec ade 209 . In addition, several juvenile cystic kidney diseases caused by various gene defects commonly lead to renal failure before adulthood 211 . Although key insights into disease mechanisms at a cellular level have been gained over the past two decades, treatment choices remain limited 212 . mTOR has an important role during cyst formation and enlargement in PKD 213, 214 . Initial studies aimed to establish whether mTOR inhibitors could ameliorate PKD in rodent models 213, 214 . With very few exceptions (female Han:SPRD rats and PCK rats) 215, 216 , these agents elicited ; deterioration in GFR in spontaneously hypertensive rat 163 No effect on renal function (serum creatinine levels) after 8 weeks of treatment 323 
Diabetes mellitus
Attenuates renal hypertrophy, mitigates albuminuria [175] [176] [177] No direct studies; use of sirolimus post-islet transplantation associated with proteinuria Long-term treatment effective in reducing tumour volume 256, 263 ; neoadjuvant use of sirolimus facilitates nephron-sparing resection 261 
Renal cell carcinoma
Temsirolimus and the TORKinib Ku0063794 inhibit tumour growth in a xenograft model of renal cell carcinoma 331 Several inhibitors tested without great success in advanced disease 332 including temsirolimus 333 , everolimus 334 , deforolimus 335 and CCI-779 (REF. 336) ANCA, anti-neutrophil cytoplasmic antibody; GBM, glomerular basement membrane; GFR, glomerular filtration rate; GN, glomerulonephritis; TORKinib, novel dual inhibitor of TORC1 and TORC2; TSC, tuberous sclerosis complex.
a profound and longlasting reduction in kidney size and an improvement in renal function. The gene prod uct of PKD1, polycystin1, interacts with TSC2, which forms a complex with the GTPbinding protein RHEB upstream of mTOR. When polycystin1 was mutated this multiprotein complex led to aberrant activation of mTORC1 in tubular epithelial cells in poly cystic mice and in patients with PKD 214 . Loss of PKD1 is also associated with increased expression and activity of ERK, which phosphorylates TSC2 and thereby increases the stimu latory effect of the TSC2/RHEB complex on mTORC1 (REF. 217 ). This molecular mechanism brings together several known signalling and cellular perturbations related to PKD1 insufficiency: increased proliferation, increased cell size and increased apoptosis 217 . Aberrant signalling in the primary cilia is a hallmark and initiating feature of PKD. Loss of cilia inhibits the basal body compartment and reduces serine-threonine protein kinase STK11-AMPKmediated inhibition of mTORC1 (REF. 218 ). This reduction in inhibition in turn, leads to increased activation of mTORC1 and increased cell size. Reduced AMPK signalling, together with increased ERK signalling, have also been identified as the cause of the high anaerobic glycolytic activity observed in human PKD1 knockout cells and in the kidneys of PKD1knockout mice 219 . Administration of metformin, AICAR (an analogue of AMP) or 2deoxyglucose reduced glycolytic activity and restored AMPK phosphory lation, thereby inhibiting mTORC1 and ameliorating cyst growth and functional decline in PKD 219, 220 . Clinical trials of mTOR inhibitors in PKD were ini tiated based on the central pathomechanistic role of mTORC1 in this disease, encouraging preclinical results in rodent models, and anecdotal reports of shrinkage of enlarged polycystic kidneys in transplant recipients receiving mTOR inhibitors 214, 221 . The two largest clini cal trials to date enrolled a total of >500 patients. The Swiss ADPKD study focused on patients with early stage ADPKD who had only slightly limited renal function and fairly small kidneys 222 , whereas the Everolimus in ADPKD Study enrolled patients with progressive dis ease, moderate to severe impairment of renal function and enlarged kidneys 223 . Both trials failed to demonstrate improvement in renal function with mTOR inhibition. Moreover, in the everolimus in ADPKD Study, an initial significant increase in GFR followed by a trend towards worse renal function was reported. In the Swiss ADPKD study, change in kidney size did not differ between the mTOR inhibitor and placebo groups after 18 months; the Everolimus in ADPKD Study demonstrated a reduction in kidney size with everolimus versus pla cebo after 6 months and a trend towards a reduction in kidney size at 12 months, which likely failed to reach significance owing to the dropout rate. Several expla nations as to why these benchtobedside approaches did not yield positive results have been suggested 224, 225 ; these relate to the short followup period for a slowly progressive disease and, in the Swiss ADPKD study, low blood trough levels of rapamycin that might have been insufficient to achieve inhibition of mTORC1 within the cystic tissue 222, 226 . In the Everolimus in ADPKD trial, the heterogeneous patient population with advanced disease, frequent adverse effects (angioedema, aphthous stomatitis and proteinuria) and hence a high dropout rate, might have obscured subgroups that could have benefited from an mTORtargeted approach 223 . A smaller Italian study (SIRENA) in 21 patients with ADPKD reported positive outcomes with sirolimus in terms of arresting kidney enlargement and reducing loss of renal parenchymal tissue 227 . Again possibly due to the short study period and small sample size, no improvement in renal function was detected. Another caveat was the high blood trough levels of rapamycin that would certainly cause substantial adverse events in the long term.
Despite the rather disappointing clinical outcomes of the adequately powered studies published to date, several smaller trials entailing different treatment protocols and more specific patient cohorts have been initiated 228, 229 . Although the preclinical data is compelling, mTOR inhibitors cannot currently be advocated as a therapeu tic option in ADPKD outside of clinical trials. Further experimental work is needed to define optimal treat ment time points and appropriate drug levels for mTOR inhibitors during the course of ADPKD. Organspecific drug targeting approaches would likely enable a reduc tion in adverse events and could enhance the desired effects of mTOR inhibitors within polycystic kidneys. Whether combined mTORC1/2 inhibition could have a role in future trials remains to be determined 230 . mTOR in renal fibrosis and CKD The role of mTOR in the induction and progression of pathology in fibrotic kidney disease is less well described than the role of mTOR in AKI. Concurrent findings indicate that the use of rapamycin following kidney injury, regardless of aetiology, reduces the subsequent development of interstitial fibrosis and/or the expression of fibrosisrelated genes in IRI 231 , transplantation 232 , adria mycin nephropathy 233 , unilateral ureteral obstruction (UUO) 234 and glomerulopathy 235, 236 . Treatment of normal rat kidney cells (NRK49F cell line) with TGFβ1 activates Rictor and mTORC2 sig nalling in a timedependent fashion, whereas knock down of Rictor (using siRNA) inhibits the expression of fibronectin and smooth muscle actin 237 . In rats subjected to UUO (a standard model of renal fibrosis that causes phenotypic transition of renal tubular epithelial cells, endothelial cells and pericytes), Rictor was upregulated in comparison to levels in shamoperated controls and colocalized with cells expressing smooth muscle actin, consistent with myofibroblast expression. Fibroblast specific deletion of Rictor produced phenotypically and functionally normal kidneys that demonstrated lower collagen content and fibrosis, apoptosis and inflamma tory cell infiltration following UUO 237 . Despite the util ity of this animal model, one must consider that UUO results in acute fibrosis, whereas interstitial fibrosis, at least in humans, usually occurs as a chronic consequence of renal injury 238 . Initial findings of mTOR activation in kidney fibro sis were limited to macrophages and myofibroblasts 239 . Administration of rapamycin mitigated the fibrotic and macrophagebased inflammation in response to UUO, and in vitro induction of fibroblastmediated fibrogenic activity in response to TGFβ. Indeed, TGFβ activates mTOR exclusively through the TSC2 pathway in fibro blasts 240 , and upregulation of TGFβinduced RhebmTORC1 signalling in interstitial myofibroblasts was abolished by rapamycin 241 . Activation of mTOR also inhibited microRNA21induced suppression of mesan gial cell protein synthesis and reduced TGFβinduced hypertrophy 242 . Fullymismatched rodent models of kidney transplan tation have also been used to evaluate the role of mTOR in chronic allograft nephropathy. As in other chronic kidney injury models, mTOR inhibition in these ani mals improved proteinuria and glomerulosclerosis 243, 244 , reduced inflammatory infiltrate 245 and decreased expres sion of fibrotic factors (TGFβ, plateletderived growth factor and CTGF) 245, 246 . Multiple mechanisms that might underlie these beneficial effects of mTOR inhibitors have been reported. Several studies noted alterations in podo cyte VEGF transcript and protein expression in vivo fol lowing treatment with mTOR inhibitors, and this finding has been replicated in vitro 247 . Treatment with sirolimus reduced VEGFC/VEGFR3 signalling, which has critical roles in lymphangiogenesis and in lymphatic endothelial cells, suggesting that inhibition of lymphangio genesis might be the mechanism of nephroprotection 248 . Plasmin activator inhibitor (PAI)1 has been implicated in fibro sis and is thought to have a critical role in extracellular matrix deposition and matrix metalloproteinase activ ity 249 . In renal transplant recipients with chronic allo graft nephropathy treated with rapamycin, glomerular and tubulointerstitial expression of PAI1 was reduced compared to those maintained on CNIs 250 . The rodent remnant kidney model involves unilat eral nephrectomy and partial infarction of the remain ing kidney leading to CKD, which is characterized by a progressive rise in systolic blood pressure and serum creatinine levels. In this model, everolimus and siroli mus have both been reported to limit the progression of renal disease 251, 252 , with decreased proteinuria, fibrosis and TGFβ expression, fibroblast activation 252 and VEGF signalling 251 . However, deleterious effects of everolimus (induction of proteinuria, interstitial fibrosis and glo merulosclerosis) have also been demonstrated in the same model 195 . These divergent findings are puzzling and it is not clear whether the observed differences are simply related to the rodent genotype.
mTOR in malignancies
Renal angiomyolipomas Angiomyolipomas (AMLs) resulting from clonal prolif eration of epithelioid cells, are the most common renal lesions in patients with TSC. These lesions mani fest as multiple and bilateral benign kidney tumours that can bleed spontaneously or cause lifethreatening haemorrhage if >4 cm in diameter 253 . Less common renal manifestations of TSC include renal cysts, RCCs, oncocytomas and FSGS. TSC is caused by mutations in either TSC1 on chromosome 9 or TSC2 on chro mosome 16 (REFS 254, 255) . Their gene products, hamartin and tuberin respectively, dimerize and func tion as a GTPaseactivating protein for Rheb, explain ing the variety of benign tumours that form across multiple organs.
Given the genetic and molecular basis of TSC, use of mTOR inhibitors has been investigated as a sys temic treatment 253, 256 . Early mTOR inhibiton in patients with TSC might prevent development of TSC lesions and alter the natural history of the disease 257 . Multiple nonrandom ized studies have found that sirolimus reduces AML tumour volume 258, 259 . In one study, rapa mycin treatment reduced mean tumour volume by 55% at 6 months and 66% at 1 year 260 , with no difference in mean tumour volume seen between years 1 and 2. Neoadjuvant use of mTOR inhibitors to facilitate nephronsparing resection has also been reported 261 . The largest study of mTOR inhibitors in TSC to date is the EXISTII trial 262 . In this study, 118 patients were randomly assigned in 2:1 ratio to receive everolimus or placebo. Inclusion criteria included age >18 years, diag nosis of TSC (or sporadic lymphangioleiomyomatosis (LAM)) and at least one AML ≥3 cm in diameter. The rate of response (defined as a 50% reduction in total AML volume) was 42% for everolimus and 0% for placebo. As a result of these findings, everolimus was FDAapproved for treatment of adults with renal AMLs and TSC who do not require immediate surgery. Longterm everolimus treat ment seems to be safe and effective in patients with TSC or sporadic LAMassociated renal AMLrelated bleed ing 263 . Currently, mTOR inhibitors are recommended as firstline therapy for patients with AML volume >3 cm who are not candidates for immediate surgery.
Renal cell carcinoma
RCCs originate in the renal cortex and constitute 80-85% of primary renal neoplasms. The role of mTOR inhib itors in the treatment of advanced RCC has been stud ied extensively 264 , although their use has been restricted largely to patients refractory to antiVEGF therapy or with mutations in PI3K. In the INTORSECT trial, 500 patients refractory to the protein kinase inhibitor (PKI) sunitinib were randomly assigned to receive either the PKI sorafenib or temsirolimus 265 . Overall survival was shorter with temsirolimus. In the BEST trial, treatment naive patients were randomly assigned to various molec ular therapies including combinations of mTOR and VEGF pathway inhibitors 266 . However, none of these combinations outperformed antiVEGF (bevacizumab) monotherapy. In the RECORD1 trial, everolimus ther apy prolonged progressionfree survival in comparison to placebo in patients with metastatic RCC that had progressed on sunitinib, sorafenib, both therapies, or cytokines 208 . In the RECORD4 trial everolimus was assessed in a secondline setting that confirmed the progressionfree survival benefit 209 . Several TORKinibs have emerged as attractive alterna tives to rapalogues in advanced RCC, owing to their dual inhibition of mTORC1 and mTORC2 and their favourable pharmacokinetic profile. Targeting of both complexes is considered theoretically advantageous, as this approach would prevent 'rapalogue resistance' caused by activation of feedback loops that arise from mTORC1 inhibition alone and produce greater cytotoxicity against malignant cells 267 . The novel TORKinib AZD2014 inhibited RCC cell survival and growth and enhanced autophagy in vitro, and inhibited RCC cell growth in a xenograft model 268 . However, a randomized Phase II study of AZD2014 ver sus everolimus in antiVEGFrefractory metastatic RCC, showed inferior progressionfree survival and overall sur vival with the TORKinib despite favourable toxicity and pharmacokinetic profiles 269 . At present, a role for these novel agents in advanced antiVEGFrefractory RCC remains uncertain. With the advent of molecular profil ing of tumours, targeted mTOR inhibition might, how ever, still prove beneficial in subgroups of patients with mTORdriven neoplasms.
Post-transplantation malignancy
In the setting of posttransplantation malignancy mTOR inhibitors have theoretical advantages over other estab lished immunosuppressive agents owing to their simul taneous stimulatory effects on certain immune cells and growth suppressive effects on malignant cells. In various animal models, sirolimus suppresses the growth and proliferation of tumours 270 . As a nutrient sensor and regulator of cell growth, tumours rely on the mTOR pathway to acquire and catabolize nutrients. Indeed, many tumours are characterized by upregulated mTOR signalling as a result of mutations in tumour suppres sors (PTEN, TSC1/2) or oncogenes (PI3K, S6K, eIF4E) 271 . Hence, most tumours are susceptible to mTOR inhibitors antibody generation in transplant recipients need further exploration • Evidence from invertebrate and rodent models suggests that mTOR inhibition can prolong life by ameliorating ageing-associated cellular decline, but whether these effects also occur in humans is unclear
Future directions
• From a pathophysiological perspective improved understanding of how mTORC1 and mTORC2 drive the pathogenesis of renal disease is paramount • Clinical trials in transplantation should aim to delineate the optimal drug combinations with mTOR inhibitors on both a temporal and intensity basis • Prospective controlled randomized trials are needed to substantiate the benefits of mTOR inhibitors to avoid or reduce certain cancers and viral infections in transplant recipients • Future drug development should not only aim to test the potential superiority of TORKinibs (novel dual inhibitors of TORC1 and TORC2) over mTOR inhibitors, but should also identify downstream mediators of mTORC1 and mTORC2, which might improve the adverse effect profile by specifically targeting pathological activation loops to varying degrees. The ability of mTOR inhibitors to directly inhibit the replication of viruses such as CMV and human herpesvirus 8 is another potential advantage of these agents 272, 273 . Despite the potential advantages of mTOR inhibi tors and some evidence of anticancer effects in trans plant recipients 274, 275 , including an antitumour effect of sirolimus early after transplantation in subgroups of liver recipients with hepatocellular carcinoma 276 , these agents have not replaced CNIs in the clinic. Reasons for this failure include a plethora of adverse effects that limit tolerability and a lack of randomized control trials showing a clear benefit of conversion to mTOR inhibitors on hard clinical outcomes, such as de novo malignancy or cancerrelated death. Nonetheless, con version to mTOR inhibitors seems to be a reasonable choice for patients with either prior nonmelanoma skin cancer 277 or newly diagnosed Kaposi sarcoma 278 . Several randomized controlled trials have demonstrated lower recurrence rates of squamous cell carcinoma (SCC) in patients with skin tumours converted to sirolimus than in those remaining on CNIs 277, 279 . In one study, conver sion of kidney transplant recipients with at least one cutaneous SCC to sirolimus reduced the incidence of new SCC at 2 years (22% in the sirolimus group versus 39% in the CNI group) 280 . In all studies, however, dis continuation of sirolimus because of adverse events was common (20-50%). Given these high discontinuation rates, balancing the optimal therapeutic dose to prevent graft rejection while avoiding doserelated toxicities remains a challenge.
In kidney transplant recipients with Kaposi sarcoma, conversion from ciclosporin to sirolimus was associ ated with complete regression of lesions by 3 months 274 .
Patients with Kaposi sarcoma show markedly increased basal P70 (S6K) activation and depressed Akt phos phorylation in peripheral blood mononuclear cells, and longterm treatment with rapamycin is associated with marked inhibition of basal and stimulated phos phorylation of both Akt and P70 (S6K) in parallel with regression of the skin neoplasm 281 . Two metaanalyses have examined the efficacy of mTOR inhibitors for prevention of de novo malignancy in kidney transplant recipients. In the first study, Knoll et al. showed a decreased incidence of cancer with sirolimus therapy (40% reduction in risk of malignancy and 56% reduction in risk of nonmelanoma skin cancer) 130 . However, excess mortality largely owing to cardio vascular disease and infection was also seen in the sirolimus group. By contrast, the second analysis (of cancer registry data) showed no benefit of sirolimus on cancer incidence, although this finding was attributed largely to an unex plained significantly increased incidence of prostate cancer in patients who received this therapy 282 . These findings, particularly the excess mortality in the first study, have dampened enthusiasm for mTOR inhibitors.
Thus, although mTOR inhibitors continue to show promise for the treatment of postkidney transplantation malignancies, their use for malignancies other than Kaposi sarcoma and nonmelanoma skin cancer remains controversial and understudied in wellpowered randomized controlled trials. Furthermore, no role is apparent for the de novo use of these agents in the prevention of cancer.
Conclusions and future perspectives
Although considerable insights have been gained, much remains to be uncovered regarding the roles of mTOR in renal physiology and disease. Moreover, the potential of mTOR inhibitors to alleviate kidney pathology and improve outcomes in kidney transplantation needs more extensive assessment, both in the laboratory and in the clinic. The advent of mTOR complex gene targeting in specific renal and immune cell populations and the avail ability of new generation pharmacologic mTOR inhibi tors is enhancing our understanding of the diverse roles of mTORC1 and mTORC2 in the regulation of kidney func tion, pathology and the autoimmune and allo immune responses that affect renal disease, patient care and trans plant survival. Areas particularly worthy of investigation and future directions (BOX 1) include the roles of mTOR in the control of tissue ageing, growth of certain cancers and resistance to specific viral infections, as well as the optimal ways to use mTOR antagonists in conjunction with other therapeutic agents in the clinic.
